CARLSBAD, Calif.--Invitrogen named two new board members to guide the development of a new division focused on applying Invitrogen's gene cloning and expression technologies to enable functional genomics studies for drug discovery, diagnostic development, and crop improvement. James Glynn was appointed senior vice-president and member of the board of directors, and Lewis Shuster, chief financial officer of Pharmacopeia, was also named to the board.
Invitrogen CEO Lyle Turner said the company is gearing up to expand upon its base of proprietary gene cloning and expression technologies and apply the technology platforms for advanced functional genomics research.